ROJAS-MARTINEZ, A. et al. Sickle cell crisis and treatment of pain. []. , 22, 4, pp.165-167. ISSN 1134-8046.  https://dx.doi.org/10.4321/S1134-80462015000400004.

Drepanocytosis includes a group of genetically inherited disorders in which low oxygen saturation rigid polymers aggregation deoxygenated hemoglobin S occurs, giving the red cell sickling and damaging the vascular endothelium through multiple mechanisms, and concomitantly blocking microcirculation producing a stimulation of nociceptors. Patients with sickle cell disease may have multiple types of pain depending on the injured structures, being the most common musculoskeletal type. The basis of pain management is the recognition and assessment of severity, since this will depend prescription analgesic treatment. The vaso-occlusive crises are the most characteristic manifestation of this disease. Once established pain, initial management should focus on providing rapid control of it, ensuring therapeutic doses of drugs, and the detection of complications. The not indicated therapies, accompanied by careful monitoring, prevention and treatment of adverse effects subtherapeutic use and treatment should be avoided. We report a 14 year old, of African origin, diagnosed with drepanocytosis and alpha thalassemia heterozygous with acute severe pain in lower limbs. The treatment of chronic pain is a multidisciplinary manner, considering nonpharmacologic strategies.

: Sickle cell disease; Drepanocytosis; Veno-occlusive crisis; Opioids; Severe pain.

        · |     · |     · ( pdf )